Jamil Khatri
A5051200199- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Colorectal and Anal Carcinomas
- Inflammatory Biomarkers in Disease Prognosis
- Esophageal Cancer Research and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Neutropenia and Cancer Infections
- Nutrition and Health in Aging
- Molecular Biology Techniques and Applications
- PARP inhibition in cancer therapy
- Ferroptosis and cancer prognosis
- Organoselenium and organotellurium chemistry
- Immunotherapy and Immune Responses
- Frailty in Older Adults
- Vanadium and Halogenation Chemistry
Marshall University
2023-2024
Christiana Care Health System
2008-2024
Edwards Comprehensive Cancer Center
2023
Union Hospital
2021
Cooper University Hospital
1996-2002
University Hospital and Clinics
1996-2002
University of South Carolina
1992-1998
University Medical Center
1996
Abstract Background Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond immunohistochemistry, microsatellite instability, tumor mutation burden (TMB) may improve benefit prediction. Methods Using treatment data genomic transcriptomic tissue profiling from an observational trial (NCT03061305), we developed Immunotherapy Response Score (IRS), a pan-tumor predictive model of PD-(L)1 benefit. IRS real-world progression free survival...
PURPOSE Guidelines advocate molecular profiling in the evaluation of advanced non–small-cell lung cancer (NSCLC) and support use plasma circulating tumor DNA (ctDNA)-based for patients with insufficient tissue. Thorough prospective clinical validation studies next-generation sequencing (NGS)-based ctDNA assays are lacking. We report multicentered InVision assay untreated NSCLC. METHODS A total 264 NSCLC were prospectively recruited, their was analyzed using a NGS detection genomic...
Tissue-based comprehensive genomic profiling (CGP) is increasingly used for treatment selection in patients with advanced cancer; however, tissue availability may limit widespread implementation. Here, we established real-world CGP and assessed performance on consecutively received samples.
Older adults with advanced cancer experience functional disability that warrants rehabilitation services; however, evidence indicates inconsistencies in referral. The purpose was to (1) identify predictors of geriatric assessment (GA)-driven referrals services and (2) explore associations between referral change function, health-related quality life (HRQoL), overall survival among older cancer.
Selective Internal Radiation (SIR) therapy with yttrium-90 microspheres has become an alternative approach to treat hepatic tumors.A single institution retrospective chart review was performed assess the safety of SIR in twenty-one patients malignancies. The radiation dose dependent upon percentage tumor involvement liver, a modification (reduction) adjusted for macroaggregated albumin (MAA) shunted lung.Twenty-one underwent twenty-five treatments microsphere primary and metastatic liver...
Abstract Purpose To examine the benefit of telehealth over current delivery options in oncology practices without genetic counselors. Methods Participants meeting cancer testing guidelines were recruited to this multi‐center, randomized trial comparing uptake services with remote (telephone or videoconference) usual care six predominantly community The primary outcome was composite counseling testing. Secondary outcomes compare telephone versus videoconference services. Results 147...
Immunotherapy response score (IRS) integrates tumor mutation burden (TMB) and quantitative expression biomarkers to predict anti-PD-1/PD-L1 [PD-(L)1] monotherapy benefit. Here, we evaluated IRS in additional cohorts. Patients from an observational trial (NCT03061305) treated with anti-PD-(L)1 were included assigned IRS-High (-H) versus -Low (-L) groups. Associations real-world progression-free survival (rwPFS) overall (OS) determined by Cox proportional hazards (CPH) modeling. Those...
A 13-year-old African-American female with erythrocytosis and three different β globins on electrophoresis βA, βS, βOsler, raised the possibility that one chromosome 11 might contain a duplicated globin gene, since there are normally only 2 genes. DNA sequence analysis showed GTG at codon 6 in exon 1, corresponding to Hb S AAT 145 3, indicating substitution of Asn for Tyr. Thus, Osler undergoes spontaneous post-translational deamidation, Asn→β Asp. Unmodified (Asn) co-migrates co-elutes...
Topotecan is a topoisomerase-I inhibitor, drug that stabilizes covalent complex of enzymes and causes strand cleavage DNA. 5-Fluorouracil (5FU) an antimetabolite interferes with DNA synthesis. Preclinical studies using human cancer cell line models have shown potential therapeutic synergy between these two drugs by showing the maximum cytolytic effect sequential 5FU followed topotecan. In current study, was used at fixed dose 375 mg/m2 given intravenously for five consecutive days on 28 day...
3073 Background: Widespread integration of systematized next generation sequencing (NGS)-based precision oncology is hindered by numerous barriers. Hence, we developed the Strata trial (NCT03061305), a screening protocol to determine impact scaled oncology. Methods: We implemented no-cost NGS on formalin fixed paraffin embedded (FFPE) clinical samples for all patients with advanced tumors, common portfolio partnered therapeutic trials, and robust infrastructure development across Precision...
3574 Background: Tissue-based h-CGP is increasingly utilized for treatment selection in patients with advanced solid tumors but has high tumor surface area [TSA] requirements (≥25mm 2 leading commercial tests). P-CGP recommended when tissue insufficient H-CGP. Here we assessed the feasibility and clinical impact on actionable biomarker identification of PCR-CGP. Methods: We performed a post-hoc, non-prespecified analysis 21,743 consecutive subjects who sent TTS PCR-CGP from 5/17-12/19 as...
Abstract Purpose Tissue-based comprehensive genomic profiling (CGP) is increasingly utilized for treatment selection in patients with advanced solid tumors, however real-world tissue availability may limit widespread implementation. Here we established CGP and assessed performance on consecutively received samples. Patients Method Post-hoc, non-prespecified analysis of 32,048 consecutive tumor samples StrataNGS, a multiplex PCR based-CGP (PCR-CGP) test, as part an ongoing observational trial...
<p>Supplementary Figure S8. shows overlap weighting propensity score analysis of the chemotherapy, anti-PD-(L)1, and chemotherapy + anti-PD-(L)1 validation cohort</p>
<p>Supplementary Data S1 shows the REMARK checklist for study</p>
<p>Supplementary Figure S5 shows robustness of Immunotherapy Response Score to self-reported race</p>